Prentiss Smith & CO Inc Regeneron Pharmaceuticals, Inc. Transaction History

Prentiss Smith & CO Inc

$148 Million
Q3 2024

A detailed history of Prentiss Smith & CO Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 2,037 shares of REGN stock, worth $1.46 Million. This represents 1.45% of its overall portfolio holdings.

Number of Shares

2,037

Previous 2,093 2.68%

Holding current value

$1.46 Million

Previous $2.2 Million 2.64%

% of portfolio

1.45%

Previous 1.54%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$1024.09 - $1201.76 $57,349 - $67,298	-56 Reduced 2.68%	2,037 $2.14 Million
Q2 2024 Jul 17, 2024	SELL	$883.2 - $1071.19 $1.28 Million - $1.56 Million	-1,452 Reduced 40.96%	2,093 $2.2 Million
Q1 2024 Apr 30, 2024	SELL	$902.69 - $993.35 $100,198 - $110,261	-111 Reduced 3.04%	3,545 $3.41 Million
Q4 2023 Feb 02, 2024	SELL	$775.18 - $881.7 $1.38 Million - $1.57 Million	-1,779 Reduced 32.73%	3,656 $3.21 Million
Q3 2023 Oct 24, 2023	SELL	$692.45 - $844.37 $105,944 - $129,188	-153 Reduced 2.74%	5,435 $4.47 Million
Q2 2023 Aug 02, 2023	SELL	$700.03 - $830.35 $11,900 - $14,115	-17 Reduced 0.3%	5,588 $4.02 Million
Q1 2023 Apr 28, 2023	SELL	$680.49 - $826.97 $44,912 - $54,580	-66 Reduced 1.16%	5,605 $4.61 Million
Q4 2022 Jan 31, 2023	SELL	$705.89 - $766.39 $160,942 - $174,736	-228 Reduced 3.87%	5,671 $4.09 Million
Q3 2022 Oct 21, 2022	SELL	$573.97 - $724.32 $84,947 - $107,199	-148 Reduced 2.45%	5,899 $4.06 Million
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $70,737 - $95,310	-129 Reduced 2.09%	6,047 $3.58 Million
Q1 2022 May 09, 2022	SELL	$595.12 - $698.43 $3.35 Million - $3.93 Million	-5,634 Reduced 47.71%	6,176 $4.31 Million
Q4 2021 Jan 28, 2022	BUY	$543.48 - $670.97 $177,717 - $219,407	327 Added 2.85%	11,810 $7.46 Million
Q3 2021 Oct 19, 2021	SELL	$574.03 - $680.96 $5,740 - $6,809	-10 Reduced 0.09%	11,483 $6.95 Million
Q2 2021 Jul 15, 2021	SELL	$472.8 - $558.54 $118,672 - $140,193	-251 Reduced 2.14%	11,493 $6.42 Million
Q1 2021 Jun 21, 2021	BUY	$446.73 - $548.2 $2.2 Million - $2.69 Million	4,916 Added 72.0%	11,744 $5.56 Million
Q4 2020 Feb 03, 2021	SELL	$478.3 - $607.98 $432,383 - $549,613	-904 Reduced 11.69%	6,828 $3.3 Million
Q3 2020 Nov 02, 2020	SELL	$544.75 - $658.21 $77,354 - $93,465	-142 Reduced 1.8%	7,732 $4.33 Million
Q2 2020 Jul 13, 2020	BUY	$493.32 - $643.92 $2,959 - $3,863	6 Added 0.08%	7,874 $4.91 Million
Q1 2020 Apr 29, 2020	SELL	$336.18 - $494.43 $2.77 Million - $4.07 Million	-8,229 Reduced 51.12%	7,868 $3.84 Million
Q4 2019 Jan 21, 2020	SELL	$274.13 - $376.51 $108,281 - $148,721	-395 Reduced 2.4%	16,097 $6.04 Million
Q3 2019 Nov 06, 2019	BUY	$273.46 - $318.39 $16,954 - $19,740	62 Added 0.38%	16,492 $4.58 Million
Q2 2019 Jul 19, 2019	BUY	$299.6 - $414.82 $4.92 Million - $6.82 Million	16,430 New	16,430 $5.14 Million
Q1 2019 Jul 01, 2019	SELL	$372.08 - $439.57 $2.59 Million - $3.06 Million	-6,951 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$335.82 - $403.04 $25,858 - $31,034	77 Added 1.12%	6,951 $2.6 Million
Q3 2018 Oct 23, 2018	SELL	$351.14 - $408.51 $1.58 Million - $1.84 Million	-4,494 Reduced 39.53%	6,874 $2.78 Million
Q2 2018 Jul 19, 2018	SELL	$284.6 - $344.99 $2.39 Million - $2.89 Million	-8,385 Reduced 42.45%	11,368 $3.92 Million
Q1 2018 Apr 20, 2018	BUY	$315.82 - $393.78 $2.23 Million - $2.78 Million	7,057 Added 55.58%	19,753 $6.8 Million
Q4 2017 Feb 13, 2018	BUY	$358.63 - $469.95 $4.22 Million - $5.53 Million	11,765 Added 1263.69%	12,696 $4.77 Million
Q3 2017 Oct 23, 2017	BUY	$431.38 - $504.0 $401,614 - $469,224	931	931 $416,000

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.6B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prentiss Smith & CO Inc with notifications on news.

Account

Prentiss Smith & CO Inc Regeneron Pharmaceuticals, Inc. Transaction History